Related Experiment Video
Updated: Aug 5, 2026
08:39
Murine Colitis Modeling using Dextran Sulfate Sodium (DSS)
Published on: January 19, 2010
Rhamnogalacturonan-I type polysaccharide from Curcuma longa attenuates DSS-induced colitis by modulating inflammatory
Seung-U Son1,2, Eun Hye Choi1, Seo Jin Park1
1Department of Food Science and Biotechnology, Kyonggi University, Suwon, 16227 Republic of Korea.
Food Science and Biotechnology
|July 31, 2026
Summary
Turmeric polysaccharides (TP) show protective effects against colitis. This study found TP strengthened the gut barrier and reduced inflammation, indicating their potential for managing colitis.
Area of Science:
- Immunology
- Gastroenterology
- Pharmacology
Background:
- Turmeric (Curcuma longa L.) is known for curcumin, but its polysaccharides (TP) are less studied.
- Inflammatory bowel disease, such as colitis, poses a significant health challenge.
- Understanding novel therapeutic agents for colitis is crucial.
Purpose of the Study:
- To investigate the protective effects of turmeric polysaccharides (TP) against colitis.
- To evaluate TP's efficacy in vitro using Caco-2 cells and in vivo using a DSS-induced colitis model.
Main Methods:
- In vitro: Assessed TP cytotoxicity and IL-1β-induced cytokine production in Caco-2 cells.
- In vivo: Induced colitis in mice using dextran sulfate sodium (DSS) and administered TP.
- Evaluated clinical outcomes, colon histology, and inflammatory markers (cytokines) at protein and mRNA levels.
Main Results:
- TP demonstrated no significant cytotoxicity in Caco-2 cells up to 100 µg/mL.
- TP suppressed IL-1β-induced interleukin and monocyte chemoattractant protein production.
- In DSS-induced colitis, TP improved clinical scores, body weight, and colon length.
- TP restored goblet cells and mucus layer integrity in the colon.
- TP modulated pro- and anti-inflammatory cytokines in serum and colonic tissues.
Conclusions:
- Turmeric polysaccharides (TP) mitigate colitis symptoms by enhancing intestinal barrier function.
- TP inhibit inflammatory signaling pathways involved in colitis pathogenesis.
- TP are a promising functional ingredient for colitis management.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...